Skip to content
Screener

Alkermes ALKS Short-Term Investments

Short-Term Investments at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$2.35B+134%
LBR
LB Pharmaceuticals IncLBRX
$44.96M
Harmony Biosciences Holdings, Inc. logo
Harmony Biosciences Holdings, Inc.HRMY
$51.52M+187%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$1.14B-14.5%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$1.05B+40.1%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$167M-46.4%

Other financials

Income statement

See full
Revenue$496.0M+27.0%
Gross profit$397.9M+16.6%
Operating income$18.4M-80.3%
Net income$501.0K-99.4%
EPS (diluted)$0.00-100%

Balance sheet

See full
Cash & equivalents$511.5M-1.9%
Total debt$1.6B+2,064%
Total equity$1.8B+11.3%
Total assets$4.4B+95.0%

Cash flow

See full
Operating cash flow-$165.7M-268%
CapEx$8.1M-37.4%
Free cash flow-$169.8M-291%

Valuation

See full
Market cap$8.32B+89.9%
Enterprise value$9.38B+139%
P/E125.9×+113×
P/S+2.1×

Profitability

See full
Gross margin84.6%-0.6pp
Operating margin7%-17.8pp
Net margin4%-19.2pp
FCF margin14.2%-17.6pp

Returns & leverage

See full
Return on equity3.9%-20.1pp
Debt / equity0.9×+0.8×
Current ratio2.3×-0.9×

Where this comes from

Reported directly by Alkermes in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.

The source filing: Alkermes’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 9:22 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-319022
Line itemJune 30, 2026December 31, 2025
CURRENT ASSETS:
Cash and cash equivalents$511,529$388,570
Restricted cash731,206
Investments—short-term145,048199,645
Receivables, net456,477334,025
Inventory298,957196,625
Prepaid expenses and other current assets110,89579,090
Total current assets1,522,9061,929,161

Item 1. Condensed Consolidated Financial Statements:

FAQ

What is Alkermes's short-term investments?
Alkermes (ALKS) reported short-term investments of $145.05M in Q2 2026.
How has Alkermes's short-term investments changed year-over-year?
Alkermes's short-term investments decreased by 70.7% year-over-year, from $494.54M to $145.05M.
What is the long-term trend for Alkermes's short-term investments?
Over 5 years (2020 to 2025), Alkermes's short-term investments has grown at a -11.2% compound annual growth rate (CAGR), from $362.07M to $199.65M.
What does short-term investments mean?
Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.

Ask your AI about Alkermes's short-term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude